Barclays PLC Increases Holdings in HilleVax, Inc. (NASDAQ:HLVX)

Barclays PLC grew its position in shares of HilleVax, Inc. (NASDAQ:HLVX) by 255.6% during the third quarter, HoldingsChannel reports. The firm owned 42,033 shares of the company’s stock after buying an additional 30,213 shares during the period. Barclays PLC’s holdings in HilleVax were worth $74,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. BML Capital Management LLC purchased a new stake in HilleVax during the 3rd quarter worth $35,000. GSA Capital Partners LLP purchased a new stake in shares of HilleVax during the third quarter worth about $126,000. Jane Street Group LLC lifted its stake in shares of HilleVax by 81.7% in the third quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock worth $139,000 after acquiring an additional 35,546 shares in the last quarter. Zacks Investment Management boosted its holdings in HilleVax by 411.9% in the third quarter. Zacks Investment Management now owns 92,803 shares of the company’s stock valued at $163,000 after purchasing an additional 74,673 shares during the last quarter. Finally, Maven Securities LTD acquired a new stake in HilleVax during the 2nd quarter valued at approximately $217,000. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

HilleVax Trading Down 2.3 %

HilleVax stock opened at $2.09 on Friday. HilleVax, Inc. has a 52 week low of $1.55 and a 52 week high of $20.22. The stock has a market cap of $104.09 million, a P/E ratio of -0.67 and a beta of 0.75. The stock has a 50 day moving average of $1.94 and a 200-day moving average of $2.68.

HilleVax (NASDAQ:HLVX) last released its earnings results on Thursday, November 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). As a group, equities analysts predict that HilleVax, Inc. will post -2.64 earnings per share for the current fiscal year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.